SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
denmark
Anti-Whaling Activist Paul Watson Arrested in Greenland, May Face Extradition to Japan
The famed campaigner was en route to intercept a new 370-foot Japanese factory whaling ship in the North Pacific when Danish police in Greenland made the surprise arrest, citing an international warrant issued by Japan.
Jul 22, 2024
Danish police on Sunday arrested prominent anti-whaling activist Paul Watson when his vessel came to port in Greenland, citing a warrant issued by Japan, a whaling nation that seeks his extradition.
Watson, a 73-year-old Canadian American who co-founded Greenpeace and founded Sea Shepherd, was traveling with 25 volunteers aboard the 236-foot M/Y John Paul DeJoria on a mission to the North Pacific for the Captain Paul Watson Foundation (CPWF), which he started after leaving Sea Shepherd in 2022.
When the vessel arrived in Nuuk, Greenland to refuel, the Danish police immediately boarded and arrested Watson.
The CPWF denounced the surprise arrest, which came as Watson planned to intercept a new Japanese factory whaling ship.
"We implore the Danish government to release Captain Watson and not entertain this politically-motivated request," Locky MacLean, CPWF's ship operations director, said in a statement.
This morning, Captain Paul Watson was arrested in Nuuk, Greenland by Danish federal police, who boarded the M/Y John Paul DeJoria as soon as it docked.
The crew had stopped to refuel while en route to the Northwest Passage as part of #OpKangeiMaru, our campaign aimed at… pic.twitter.com/ANWoRFiR42
— Captain Paul Watson Foundation 🐋🏴☠️ (@CaptPaulWatson) July 21, 2024
Sunday's arrest came as the M/Y John Paul DeJoria was making its way to the North Pacific via the Northwest Passage after setting off from Dublin. The CPWF team aimed to intercept the Kangei Maru, a new 370-foot, $48 million Japanese factory whaling ship that's equipped with state-of-the-art drones that expedite the killing of whales.
CPWF argues that the launch of the new vessel signals Japan's ambitions to restart commercial whaling on the high seas—international waters—in the North Pacific and the Southern Ocean as early as 2025. Japan long whaled the high seas in defiance of international law, under the guise of scientific research, but in recent years it has shifted to whaling in its own territorial waters, which extend 200 nautical miles from its shores.
Watson, who is known for confrontational tactics, was the star of the Animal Planet television show Whale Wars that ran from 2008 until 2015, in which he lead efforts to disrupt Japanese whaling on the high seas.
Over a dozen police and SWAT team members took part in Watson's arrest in Greenland, an autonomous territory of Denmark. He was handcuffed and taken to local detention. A judge denied him bail on the grounds that he was a flight risk, citing a 2012 case from Germany in which he fled house arrest; he will be held in Nuuk until August 15 as authorities assess his possible extradition to Japan, where he could face up to 15 years in jail, The New York Timesreported.
The nature of Japan's charges against Watson was not specified in media reports. The Interpol arrest warrant cited by Danish police may be an old one, according to CPWF. MacLean said the warrant had "disappeared" from public view a few months ago and may have been made confidential, possibly as a tactic to lull Watson into a false sense of security when traveling internationally.
Keep ReadingShow Less
Sanders Warns 'Unjustifiably High' Prices of Weight Loss Drugs Could Bankrupt US Health System
"There is no rational reason, other than greed, for Novo Nordisk to charge Americans struggling with obesity $1,349 for Wegovy when this exact same product can be purchased for just $186 in Denmark," said the senator.
May 15, 2024
Releasing the U.S. Senate Health, Education, Labor, and Pensions Committee's findings on the prices of weight loss drugs in the United States, Sen. Bernie Sanders on Wednesday ramped up pressure on a Danish pharmaceutical company to lower the "outrageously high" prices of Ozempic and Wegovy, warning that the current pricing could bankrupt the country's healthcare system.
As chairman of the Senate HELP Committee, Sanders (I-Vt.) is leading an investigation into Novo Nordisk's weight loss drug pricing, and the report published Wednesday is the result of modeling his staff completed to show how the medications' exorbitant prices could impact prescription drug pricing across the United States.
The committee found that if half of all U.S. adults with obesity took Wegovy and other diabetes drugs that have recently been approved for weight loss, it could cost $411 billion per year. In 2022, Americans spent $406 billion on all retail prescription drugs.
Medicare and Medicaid would spend an estimated $166 billion per year on the medications if half of the programs' patients used them, rivaling the $175 billion the programs spent on prescription drugs in 2022.
"Today's report makes it crystal clear: The outrageously high price of Wegovy and other weight loss drugs have the potential to bankrupt Medicare and our entire health care system," said Sanders.
The projected costs are a far cry from what patients in Denmark and other European countries would pay for the same drugs.
Americans currently pay $969 per month for Ozempic and $1,349 per month for Wegovy. While the two drugs have the same active ingredient, the former is typically used to treat Type 2 diabetes and the latter is for weight loss and management.
Ozempic costs just $155 in Canada, $71 in France and $59 in Germany. Danish patients pay just $186 per month for Wegovy, while the medication costs $137 in Germany and $92 in the U.K.
Sanders' report says that Novo Nordisk's prices are "especially egregious" considering the fact that the company could make a profit off manufacturing them for less than $5 per month.
"The unjustifiably high prices of these weight loss drugs could also cause a massive spike in prescription drug spending that could lead to an historic increase in premiums for Medicare and everyone who has health insurance," said the senator. "There is no rational reason, other than greed, for Novo Nordisk to charge Americans struggling with obesity $1,349 for Wegovy when this same exact product can be purchased for just $186 in Denmark."
The report cites the North Carolina state health plan's decision last month to end coverage for Wegovy and similar medications.
The plan administrators "estimated that continuing coverage for Wegovy at its current price would require them to double insurance premiums. Faced with impossible choices, the health plan eliminated coverage," reads the report.
The reason nearly 20,000 teachers and other state employees in North Carolina lost access to the drugs, the report emphasizes, "was not because there were not enough drugs to meet demand, but because Novo Nordisk refused to lower prices to make those drugs widely available."
Thirty-five state Medicaid programs do not cover the medications at all, the HELP Committee noted, due to the price.
"As important as these drugs are, they will not do any good for the millions of patients who cannot afford them," reads the report. "Further, if the prices for these products are not substantially reduced, they have the potential to bankrupt Medicare, Medicaid, and our entire healthcare system."
The committee found that if Novo Nordisk made the U.S. price of Wegovy equal to what Danish patients pay, the healthcare system could pay for new weight loss drugs for 100% of adults with obesity annually for less than what it costs to cover just 25% of those patients at the current drug prices.
The healthcare system would save up to $317 billion per year, according to the committee's modeling.
The report was released days after Sanders appealed to the Danish government in the pages of one of the country's largest newspapers, Politiken, calling on officials to force Novo Nordisk to lower U.S. prices.
"As many Danes may know, I have long admired the welfare system that has been built up in Denmark," wrote Sanders. "When I was a candidate for the presidency, I often pointed out that the United States could learn a lot from Denmark in terms of access to healthcare and education, as well as respect for the environment and workers' rights. There is a reason why Denmark is considered one of the happiest places on Earth in international surveys. The Danish people should be proud of what you have managed to achieve."
"So now I want to appeal to the people of Denmark and the charitable foundation that owns this hugely profitable company," he continued. "Help the American people do something about the epidemic of obesity and diabetes we are facing."
Pelle Dragsted, a member of Danish Parliament for the Red-Green Alliance and a democratic socialist, applauded Sanders' op-ed.
"Healthcare is a human right," said Dragsted on Monday. "Having an illness should never be the ruin of anyone. Our message to Novo Nordisk is clear: Choose basic decency and social responsibility over profit—lower your prices in the U.S."
Keep ReadingShow Less
Sanders Launches Probe of 'Outrageously Overpriced' Ozempic and Wegovy
The Senate Health, Education, Labor, and Pensions Committee chair said that the popular medications "will not do any good for the millions of patients who cannot afford them."
Apr 24, 2024
U.S. Sen. Bernie Sanders on Wednesday opened an investigation into an "outrageously overpriced" medication manufactured by a Denmark-based company whose value by market capitalization is larger than the Scandinavian country's gross domestic product.
Sanders (I-Vt.), who chairs the Senate Health, Education, Labor, and Pensions (HELP) Committee, sent a letter to Lars Fruergaard Jørgensen, CEO of Novo Nordisk. The company makes semaglutide, a glucagon-like peptide-1 (GLP-1) agonist used to treat Type 2 diabetes under the brand name Ozempic and, when sold as Wegovy, to treat obesity in adults with at least one weight-related comorbidity.
"The scientists at Novo Nordisk deserve great credit for developing these drugs that have the potential to be a game-changer for millions of Americans struggling with Type 2 diabetes and obesity," Sanders acknowledged. "As important as these drugs are, they will not do any good for the millions of patients who cannot afford them."
"Further, if the prices for these products are not substantially reduced they also have the potential to bankrupt Medicare, Medicaid, and our entire healthcare system," he added.
Sanders continued:
Today, Novo Nordisk is charging patients in the United States up to 15 times more for Ozempic and Wegovy than it charges patients in Canada, Europe, or Japan. For example, your company charges $969 in the United States for one month of Ozempic but just $155 in Canada and just $59 in Germany. Further, Novo Nordisk charges Americans $1,349 for one month Wegovy but just $140 in Germany and just $92 in the United Kingdom.
"Meanwhile," the senator noted, "researchers at Yale University estimate that both of these drugs can be profitably manufactured for less than $5 a month."
"The result of these astronomically high prices is that Ozempic and Wegovy are out of reach for millions of Americans who need them," Sanders said. "Unfortunately, Novo Nordisk's pricing has turned drugs that could improve people's lives into luxury goods, all while Novo Nordisk made over $12 billion in profits last year—up 76% from 2021. That is unacceptable."
As of March 2024, Novo Nordisk was Europe's most highly valued company by market capitalization. Its $554 billion market cap is significantly higher than Denmark's annual gross domestic product of approximately $410 billion, according to International Monetary Fund figures.
Sanders also pointed out that Novo Nordisk is charging different prices for Ozempic and Wegovy, even though they're "the exact same drug."
"Novo Nordisk charges Americans with obesity nearly $400 more every month than those with Type 2 diabetes for the same product provided in similar doses," he wrote.
"The unjustifiably high prices of Ozempic and Wegovy are already straining the budgets of Medicare and Medicaid and severely limiting access for patients who need these drugs," the letter says. "Last year, researchers at Vanderbilt University's Department of Health Policy and the University of Chicago's Department of Medicine estimated in the New England Journal of Medicine that it would cost Medicare over $150 billion a year to cover Wegovy and other similar weight loss drugs."
"To put this in perspective, the cost of all retail prescription drugs covered by Medicare in 2022 was less than $130 billion," Sanders added.
"As chairman of the committee, I am asking Novo Nordisk to substantially reduce the price of Ozempic and Wegovy so that these important drugs can be available to Americans with Type 2 diabetes and obesity," he wrote.
Existing law empowers the government to step in to lower drug prices in service of the public interest. Under the Bayh-Dole Act of 1980—legislation meant to promote the commercialization and public availability of government-funded inventions—federal agencies reserve the right to "march in" and authorize price-lowering generic alternatives to patented medications developed with public funding.
However, U.S. administrations—including President Joe Biden's—have been loath to exercise "march-in" rights.
Under pressure from the public and lawmakers led by Sanders, Novo Nordisk last year announced that it would cut prices by up to 75% for some of its insulin products.
Responding to Wednesday's letter, Pharmaceutical Research and Manufacturers of America—Big Pharma's leading lobbyist—accused Sanders of "attacking an innovative company to advance a political agenda instead of addressing the real cause of affordability challenges."
Noting Novo Nordisk's bigger-than-Denmark market cap, Warren Gunnels, the HELP Committee's majority staff director, wrote on social media that the company "made over $12 billion in profits last year by, among other things, charging Americans $969 for Ozempic while it can be purchased for $59 in Germany and costs $5 to make."
"Our political agenda is to end this greed," he added. "Guilty. As. Charged."
Keep ReadingShow Less
Most Popular